HOME > ARCHIVE

ARCHIVE

RESEARCH & DEVELOPMENT NEWS IN BRIEF

November 15, 2004
Teijin: Med., Pharm Business Sales Up 3.2% to \47.4 Bil.

November 15, 2004
Monitor

November 15, 2004
Gene Chip Accounts for 65% of Affymetrix Japan's Sales

November 15, 2004
DIAGNOSTIC NEWS IN BRIEF

November 15, 2004
PhRMA Publishes Japanese Version of Principles for Conducting Clinical Trials

November 15, 2004
OTC NEWS IN BRIEF

November 15, 2004
Mediceo HD Forms Capital Tie-up with Chain Management

November 15, 2004
MEDICAL DEVICE NEWS IN BRIEF

November 15, 2004
Tokyo CRO Establishes Its Subsidiary Tokyo CSO

November 15, 2004
Yamanouchi: Net Profits Down 30.9% due to One-time Costs Related to Merger

November 15, 2004
BUSINESS NEWS IN BRIEF

November 15, 2004
Fujisawa: Sales Up 4.1% to \204.5 Bil.

November 15, 2004
AnGes MG Expecting 1st Product Launch in 2006

November 8, 2004
Alan Bootes to Step Down as President of Pfizer Japan

November 8, 2004
BULLETIN

November 8, 2004
WORLD NEWS IN BRIEF

November 8, 2004
MEDICAL DEVICE NEWS IN BRIEF

November 8, 2004
REGULATORY NEWS IN BRIEF

November 8, 2004
DIAGNOSTIC NEWS IN BRIEF

November 8, 2004

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…